EE04275B1 - Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid - Google Patents
Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonidInfo
- Publication number
- EE04275B1 EE04275B1 EEP200000613A EEP200000613A EE04275B1 EE 04275 B1 EE04275 B1 EE 04275B1 EE P200000613 A EEP200000613 A EE P200000613A EE P200000613 A EEP200000613 A EE P200000613A EE 04275 B1 EE04275 B1 EE 04275B1
- Authority
- EE
- Estonia
- Prior art keywords
- processes
- preparation
- pharmaceutical compositions
- quinoline derivatives
- quinoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9801474A SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Quinoline Derivatives |
| PCT/SE1999/000676 WO1999055678A1 (en) | 1998-04-27 | 1999-04-26 | Quinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200000613A EE200000613A (et) | 2002-04-15 |
| EE04275B1 true EE04275B1 (et) | 2004-04-15 |
Family
ID=20411103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200000613A EE04275B1 (et) | 1998-04-27 | 1999-04-26 | Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1073639B1 (cs) |
| JP (1) | JP4045069B2 (cs) |
| KR (1) | KR100571534B1 (cs) |
| CN (1) | CN1113057C (cs) |
| AP (1) | AP1293A (cs) |
| AT (1) | ATE228505T1 (cs) |
| AU (1) | AU747550B2 (cs) |
| BR (1) | BR9909925B1 (cs) |
| CA (1) | CA2329788C (cs) |
| CZ (1) | CZ297439B6 (cs) |
| DE (1) | DE69904162T2 (cs) |
| DK (1) | DK1073639T3 (cs) |
| EE (1) | EE04275B1 (cs) |
| ES (1) | ES2188242T3 (cs) |
| HK (1) | HK1036618A1 (cs) |
| HR (1) | HRP20000726B1 (cs) |
| HU (1) | HU227709B1 (cs) |
| ID (1) | ID26277A (cs) |
| IL (2) | IL138160A0 (cs) |
| IS (1) | IS2082B (cs) |
| ME (1) | ME00870B (cs) |
| NO (1) | NO315606B1 (cs) |
| NZ (1) | NZ506641A (cs) |
| OA (1) | OA11547A (cs) |
| PL (1) | PL190441B1 (cs) |
| PT (1) | PT1073639E (cs) |
| RS (1) | RS50029B (cs) |
| RU (1) | RU2197481C2 (cs) |
| SE (1) | SE9801474D0 (cs) |
| TR (1) | TR200003061T2 (cs) |
| UA (1) | UA60354C2 (cs) |
| WO (1) | WO1999055678A1 (cs) |
| ZA (1) | ZA200004601B (cs) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) * | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| KR100908655B1 (ko) | 2002-11-27 | 2009-07-21 | 엘지디스플레이 주식회사 | 데이터 공급시간의 변조방법과 이를 이용한액정표시장치의 구동방법 및 장치 |
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
| US7838522B2 (en) | 2004-11-17 | 2010-11-23 | Ares Trading S.A. | Benzothiazole formulations and use thereof |
| US7973039B2 (en) | 2004-12-21 | 2011-07-05 | Merck Serono Sa | Sulfonyl amino cyclic derivatives and use thereof |
| JP4950070B2 (ja) | 2005-01-31 | 2012-06-13 | メルク セローノ ソシエテ アノニム | Ｎ−ヒドロキシアミド誘導体及びその使用 |
| BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 ｊｎｋ 억제제 |
| WO2007025991A2 (en) | 2005-09-01 | 2007-03-08 | Ares Trading S.A. | Treatment of optic neuritis |
| CN103333107A (zh) * | 2005-10-19 | 2013-10-02 | 泰华制药工业有限公司 | 拉奎尼莫钠晶体及其制备方法 |
| BRPI0713694A2 (pt) * | 2006-06-12 | 2012-10-30 | Teva Pharma | composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica |
| EP2682120B1 (en) | 2007-12-20 | 2016-08-03 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| NZ591315A (en) * | 2008-09-03 | 2012-08-31 | Teva Pharma | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| KR20120045032A (ko) * | 2009-07-30 | 2012-05-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 크론병의 치료 |
| HUE029983T2 (en) | 2009-08-10 | 2017-04-28 | Teva Pharma | Treatment of BDNF-related diseases with laquinimod |
| PT2542079E (pt) * | 2010-03-03 | 2014-07-18 | Teva Pharma | Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato |
| EA201290837A1 (ru) | 2010-03-03 | 2013-05-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение волчаночного нефрита с применением лаквинимода |
| WO2011109536A1 (en) * | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus arthritis using laquinimod |
| WO2011116091A1 (en) | 2010-03-17 | 2011-09-22 | Novartis Ag | Dispenser |
| JP5881691B2 (ja) | 2010-07-09 | 2016-03-09 | アクティブ バイオテック エイビー | キノリン−３−カルボキサミドの製造方法 |
| EP3213636A1 (en) * | 2010-07-09 | 2017-09-06 | Teva Pharmaceutical Industries, Ltd. | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| MX2013000332A (es) * | 2010-07-09 | 2013-02-26 | Teva Pharma | 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-dihidroquinolina-3-ca rboxamida, sales y usos de la misma. |
| EP2444086A1 (en) | 2010-10-22 | 2012-04-25 | Almirall, S.A. | Combinations comprising DHODH inhibitors and COX inhibitors |
| KR20140101333A (ko) | 2011-10-12 | 2014-08-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 및 핑골리모드의 조합을 이용한 다발성 경화증의 치료 |
| TW201345527A (zh) * | 2012-02-03 | 2013-11-16 | Teva Pharma | 拉喹莫德於治療對第一線抗－ＴＮＦα療法無效之克隆氏症患者之用途 |
| MX2014009889A (es) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) * | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| US8975279B2 (en) | 2012-11-07 | 2015-03-10 | Teva Pharmaceutical Industries, Ltd. | Amine salts of laquinimod |
| RU2545056C2 (ru) * | 2012-12-10 | 2015-03-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) | Противовоспалительное и анальгетическое средство на основе изопропиламида 1,2-дигидро-1н-2-оксоцинхониновой кислоты |
| MX2015010296A (es) * | 2013-02-15 | 2016-05-05 | Teva Pharma | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. |
| KR20150143499A (ko) | 2013-03-14 | 2015-12-23 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 개선된 제조방법 |
| AU2015253330A1 (en) | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
| US9956212B2 (en) | 2014-09-23 | 2018-05-01 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of multiple myeloma |
| KR102525805B1 (ko) | 2014-11-19 | 2023-04-25 | 액티브 바이오테크 에이비 | 백혈병 치료용 퀴놀린 카르복사미드 |
| DK3886858T3 (da) | 2019-12-19 | 2022-08-22 | Active Biotech Ab | Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering |
| WO2021175924A1 (en) | 2020-03-03 | 2021-09-10 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| KR20230043916A (ko) | 2020-07-23 | 2023-03-31 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 골수증식성 신생물의 새로운 치료학적 표적으로서 s100 단백질 |
| AU2022208424A1 (en) | 2021-01-18 | 2023-08-24 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
| KR20240012436A (ko) | 2021-05-25 | 2024-01-29 | 액티브 바이오테크 에이비 | 복수의 타스퀴니모드 입자 및 그 용도 |
| WO2023275248A1 (en) | 2021-07-02 | 2023-01-05 | Active Biotech Ab | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
-
1998
- 1998-04-27 SE SE9801474A patent/SE9801474D0/xx unknown
-
1999
- 1999-04-26 KR KR1020007011944A patent/KR100571534B1/ko not_active IP Right Cessation
- 1999-04-26 AU AU43013/99A patent/AU747550B2/en not_active Ceased
- 1999-04-26 CZ CZ20003849A patent/CZ297439B6/cs not_active IP Right Cessation
- 1999-04-26 RS YUP-612/00A patent/RS50029B/sr unknown
- 1999-04-26 DK DK99947036T patent/DK1073639T3/da active
- 1999-04-26 ES ES99947036T patent/ES2188242T3/es not_active Expired - Lifetime
- 1999-04-26 PT PT99947036T patent/PT1073639E/pt unknown
- 1999-04-26 NZ NZ506641A patent/NZ506641A/en not_active IP Right Cessation
- 1999-04-26 HU HU0102084A patent/HU227709B1/hu not_active IP Right Cessation
- 1999-04-26 OA OA1200000301A patent/OA11547A/en unknown
- 1999-04-26 RU RU2000129672/04A patent/RU2197481C2/ru not_active IP Right Cessation
- 1999-04-26 PL PL99343420A patent/PL190441B1/pl unknown
- 1999-04-26 EP EP99947036A patent/EP1073639B1/en not_active Expired - Lifetime
- 1999-04-26 TR TR2000/03061T patent/TR200003061T2/xx unknown
- 1999-04-26 CA CA002329788A patent/CA2329788C/en not_active Expired - Fee Related
- 1999-04-26 AT AT99947036T patent/ATE228505T1/de active
- 1999-04-26 JP JP2000545838A patent/JP4045069B2/ja not_active Expired - Lifetime
- 1999-04-26 ID IDW20002183A patent/ID26277A/id unknown
- 1999-04-26 BR BRPI9909925-0A patent/BR9909925B1/pt not_active IP Right Cessation
- 1999-04-26 AP APAP/P/2000/001933A patent/AP1293A/en active
- 1999-04-26 UA UA2000085078A patent/UA60354C2/uk unknown
- 1999-04-26 DE DE69904162T patent/DE69904162T2/de not_active Expired - Lifetime
- 1999-04-26 EE EEP200000613A patent/EE04275B1/xx unknown
- 1999-04-26 IL IL13816099A patent/IL138160A0/xx active IP Right Grant
- 1999-04-26 ME MEP-2000-612A patent/ME00870B/me unknown
- 1999-04-26 WO PCT/SE1999/000676 patent/WO1999055678A1/en active IP Right Grant
- 1999-04-26 CN CN99805581A patent/CN1113057C/zh not_active Expired - Fee Related
-
2000
- 2000-08-30 IL IL138160A patent/IL138160A/en not_active IP Right Cessation
- 2000-08-31 IS IS5615A patent/IS2082B/is unknown
- 2000-09-01 ZA ZA200004601A patent/ZA200004601B/en unknown
- 2000-10-19 NO NO20005254A patent/NO315606B1/no not_active IP Right Cessation
- 2000-10-26 HR HR20000726A patent/HRP20000726B1/xx not_active IP Right Cessation
-
2001
- 2001-08-07 HK HK01105489A patent/HK1036618A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE04275B1 (et) | Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid | |
| EE04464B1 (et) | Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid | |
| EE200100431A (et) | 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine | |
| EE04673B1 (et) | Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid | |
| NO20001409L (no) | Karboksamidotiazolderivater, fremgangsmÕte for fremstilling derav og farmasøytiske blandinger | |
| EE9500064A (et) | Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid | |
| EE05081B1 (et) | Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid | |
| EE200200487A (et) | Asetidiini derivaadid, nende valmistamismeetodid ja farmatseutiline kompositsioon | |
| EE200200095A (et) | Sulfonüülkarboksamiidi derivaadid, nende kasutamine, ravim ja nende valmistamismeetod | |
| EE200100252A (et) | Pürimidiinderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja sellevalmistamismeetod, kombinatsioon ning saadus | |
| EE04721B1 (et) | Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine | |
| HUP0105133A3 (en) | Quinoline derivatives and quinazoline derivatives, pharmaceutical compositions containing them and their use | |
| EE04915B1 (et) | Kinuklidiinderivaadid, nende valmistamismeetod, vahehendid, farmatseutiline kompositsioon ja nende kasutamine | |
| EE03680B1 (et) | Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid | |
| EE200000707A (et) | Oksasolidinooni derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid | |
| EE200300207A (et) | Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon | |
| EE04276B1 (et) | Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid | |
| NO20016038D0 (no) | Benzenderivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende de samme | |
| EE200000596A (et) | Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja kasutamine ning vaheühend ja selle valmistamismeetod | |
| HUP0102766A3 (en) | Aminomethylcarboxylic acid derivatives, their pharmaceutical use and pharmaceutical compositions comprising them | |
| DK1128831T3 (da) | Farmaceutisk moxifloxacinpræparat | |
| EE200000037A (et) | Atsüülpiperasinüülpürimidiinide derivaadid, nende valmistamine ja kasutamine ravimitena | |
| EE9800302A (et) | Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat | |
| EE03825B1 (et) | 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid | |
| EE04346B1 (et) | Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20101231 |